6,963 publications from this institution
The Absorb BVSs (Abbott Vascular, Santa Clara, CA; hereafter referred to as BVSs) is a 150 µm thick bioresorbable poly(l-lactide) scaffold with a conformal bioresorbable poly(d, l-lactide) coating (total thickness 7 µm) that elutes everolimus. Randomized trials comparing this device to the XIENCE cobalt-chromium everolimus-eluting stent (CoCr-EESs; Abbott Vascular) were done to support regulatory approval in Europe, Asia, and the United States, and have only recently been reported. These studies were designed to show the noninferiority of the BVSs compared with the CoCr-EESs for 1-year clinical and angiographic outcomes, since improved results with the BVSs compared with drug-eluting stents are not expected to become evident until 3-5 years after implantation. However, none of these trials were powered to exclude small differences in composite adverse event rates between devices, or to detect differences in rarely occurring safety endpoints, and their outcomes according to specific patient and lesion characteristics. Currently, several meta-analyses have been published [1-7]. In this chapter, we present the summary of what we have learned from these meta-analyses.
A hundred years ago the main treatments for obstructive lung disease were adrenal gland extracts, herbally-derived sympathomimetic ephedrine and anticholinergics, such as atropine. There have been extraordinary advancers in the pharmacological therapy of asthma and COPD, yet the major classes of therapy we use today are based on these original therapies – long-acting β<sub>2</sub>-agonists (LABA) derived from adrenaline and muscarinic receptor antagonists (LAMA) and inhaled corticosteroids (ICS) developed from the adrenal cortex hormone cortisol. Triple fixed-dose inhalers containing all 3 drugs have now been developed and are convenient for some patients. In asthma, by far the greatest advance has been the Introduction of ICS for control of the underlying eosinophilic inflammation of the airways. Although ICS are effective in most patients, there is often very poor adherence as symptoms are intermittent. In a new strategy, instead of a short-acting β<sub>2</sub>-agonist, such as salbutamol, patients use a reliever inhaler containing a rapidly-acting LABA formoterol combined with an ICS. This provides much better control of asthma and is a simple strategy for most patients. At the other end of the spectrum, patients with eosinophilic severe asthma not controlled on conventional therapies may now be controlled with biologics, which include antibodies against immunoglobulin-E, interleukin-5 and interleukin-4 receptor. In COPD the mainstay of treatment is LABA and LAMA, often as a combination inhaler, whereas ICS are only effective in a proportion of patients that also have eosinophilic inflammation. New safe anti-inflammatory treatments are needed to prevent the progression and exacerbations of COPD.
